

# Visiting Professors

A case-based discussion on the management of lung cancer in the adjuvant, locally advanced and metastatic settings

## Select Publications

- Belani C et al. **Phase III study of maintenance gemcitabine (G) and best supportive care (BSC) versus BSC, following standard combination therapy with gemcitabine-carboplatin (G-Cb) for patients with advanced non-small cell lung cancer (NSCLC).** *Proc ASCO* 2010;Abstract 7506.
- Cappuzzo F et al. **Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: A multicentre, randomised, placebo-controlled phase 3 study.** *Lancet Oncol* 2010;11(6):521-9. Abstract
- Cataldo VD et al. **Treatment of non-small-cell lung cancer with erlotinib or gefitinib.** *N Engl J Med* 2011;364(10):947-55. Abstract
- Ciuleanu T et al. **Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase 3 study.** *Lancet* 2009;374(9699):1432-40. Abstract
- D'Angelo SP et al. **A case series of dose-limiting peripheral edema observed in patients treated with pemetrexed.** *J Thorac Oncol* 2011;6(3):624-6. Abstract
- Douillard JY et al. **Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIa non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): A randomised controlled trial.** *Lancet Oncol* 2006;7:719-27. Abstract
- Herbst RS et al. **TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.** *J Clin Oncol* 2005;23:5892-9. Abstract
- Janjigian YY et al. **Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib.** *Proc ASCO* 2011;Abstract 7525.
- Keedy VL et al. **American Society of Clinical Oncology provisional clinical opinion: Epidermal growth factor receptor (EGFR) mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy.** *J Clin Oncol* 2011;29(15):2121-7. Abstract
- Kreuter M et al. **Randomized phase II trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed (CPx) versus cisplatin and vinorelbine (CVb): TREAT.** *Proc ASCO* 2011;Abstract 7002.
- Kris MG et al. **Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC).** *Proc ASCO* 2011;Abstract CRA7506.
- Patel JD et al. **Treatment rationale and study design for the pointbreak study: A randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer.** *Clin Lung Cancer* 2009;10(4):252-6. Abstract
- Paz-Ares LG et al. **PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC).** *Proc ASCO* 2011;Abstract CRA7510.
- Perol M et al. **Maintenance with either gemcitabine or erlotinib versus observation with predefined second-line treatment after cisplatin-gemcitabine induction chemotherapy in advanced NSCLC: IFCT-GFPC 0502 phase III study.** *Proc ASCO* 2010;Abstract 7507.

Quoix E et al. **Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial.** *Lancet* 2011;378(9796):1079-88. **Abstract**

Ramalingam SS et al. **Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: Analysis of Eastern Cooperative Oncology Group trial 4599.** *J Clin Oncol* 2008;26(1):60-5. **Abstract**

Sandler A et al. **Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.** *N Engl J Med* 2006;355(24):2542-50. **Abstract**

Satoh H et al. **Low-dose gefitinib treatment for patients with advanced non-small cell lung cancer harboring sensitive epidermal growth factor receptor mutations.** *J Thorac Oncol* 2011;6(8):1413-7. **Abstract**

Scagliotti G et al. **Overall survival improvement in patients with lung cancer treated with denosumab versus zoledronic acid.** Program and abstracts of the 14<sup>th</sup> World Conference on Lung Cancer, July 3-7, 2011. **Abstract**

Shaw AT et al. **Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.** *J Clin Oncol* 2009;27(26):4247-53. **Abstract**

Temel J et al. **Early palliative care for patients with metastatic non-small-cell lung cancer.** *N Engl J Med* 2010;363(8):733-42. **Abstract**

Chemotherapy with or without bevacizumab in treating patients with Stage IB, Stage II, or Stage IIIA non-small lung cancer that was removed by surgery. **NCT00324805**